Literature DB >> 3403093

High biliary elimination of ceftriaxone in man.

J M Brogard1, J F Blickle, F Jehl, J P Arnaud, D Paris-Bockel, H Monteil.   

Abstract

Biliary elimination of ceftriaxone was studied in man using chromatography (HPLC). After a single i.v. administration of 2 g of ceftriaxone to 6 normal subjects, a peak concentration of 565 +/- s.e.m. 347 micrograms/ml was reached during the 1st h in the collected duodenal fluid, and 1.4 +/- 0.5% of the given dose was recovered within 4 h. In 10 cholecystectomized patients provided with a T-drain, a maximal biliary concentration of 1,078 +/- 158 micrograms/ml was measured during the 2nd h after i.v. injection of 2 g of ceftriaxone and the 24-h recovery was 9.5 +/- 2.9%. Intraoperative samples obtained in 12 patients undergoing cholecystectomy 1 h after i.v. administration of 2 g of the antibiotic, gave the following results: serum concentration 199 +/- 10 micrograms/ml, choledochal bile = 5,259 +/- 1,085 micrograms/ml, gallbladder bile 4,533 +/- 809 micrograms/ml. These data indicate an excellent biliary elimination of ceftriaxone in comparison with other beta-lactams previously studied under the same conditions and point to be a promising therapeutic potential in biliary tract infections.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3403093

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  11 in total

1.  Acute necrotizing cholecystitis: a rare complication of ceftriaxone-associated pseudolithiasis.

Authors:  Sendia Kim; Kathleen M Gura; Mark Puder
Journal:  Pediatr Surg Int       Date:  2006-02-17       Impact factor: 1.827

Review 2.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Clinical pharmacokinetics of newer antibacterial agents in liver disease.

Authors:  J F Westphal; J M Brogard
Journal:  Clin Pharmacokinet       Date:  1993-01       Impact factor: 6.447

4.  Computed tomography findings of ceftriaxone-associated biliary pseudocholelithiasis in adults.

Authors:  Rika Yoshida; Takeshi Yoshizako; Takashi Katsube; Hajime Kitagaki
Journal:  Jpn J Radiol       Date:  2019-10-25       Impact factor: 2.374

5.  A case of ceftriaxone-associated biliary pseudolithiasis in an elderly patient with renal dysfunction.

Authors:  Shuichi Abe
Journal:  IDCases       Date:  2017-06-27

6.  Usefulness of Endoscopic Managements in Patients with Ceftriaxone-Induced Pseudolithiasis Causing Biliary Obstruction.

Authors:  Yasuhiro Doi; Yasushi Takii; Hiroyuki Ito; Norihiko Jingu; Kentaro To; Sinichiro Kimura; Koichi Kimura; Kensaku Sanefuji; Hirofumi Ikeda; Sayaka Tachibana; Takeshi Otsuka
Journal:  Case Rep Med       Date:  2017-11-02

7.  Ceftriaxone-associated nephrolithiasis and gallstone in adults.

Authors:  Ghodsiyeh Azarkar; Motahare Mahi Birjand; Alireza Ehsanbakhsh; Bita Bijari; Mohammad Reza Abedini; Masood Ziaee
Journal:  Drug Healthc Patient Saf       Date:  2018-12-12

8.  Ceftriaxone-associated Pseudolithiasis in the Gallbladder and Bile Duct of an Elderly Patient.

Authors:  Akane Yamabe; Atsushi Irisawa; Hiroto Wakabayashi; Takuya Tsunoda; Keiichi Tominaga
Journal:  Intern Med       Date:  2020-07-14       Impact factor: 1.271

9.  Ceftriaxone-associated Pseudolithiasis in Elderly People: Frequency and Risk Factors.

Authors:  Kiyoshi Hotta; Naohide Hashimura; Masaki Takatsuka; Tomoki Matsuyama; Kouichirou Nakagawa; Tsuneo Yabusako; Shuhei Hosomi; Yasuhiro Fujiwara
Journal:  Intern Med       Date:  2021-12-15       Impact factor: 1.271

Review 10.  Role of cephalosporins in the era of Clostridium difficile infection.

Authors:  Mark H Wilcox; James D Chalmers; Carl E Nord; Jane Freeman; Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2016-09-22       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.